Cytarabine; Daunorubicin Patent Expiration

Cytarabine; Daunorubicin is used for treating newly-diagnosed therapy-related acute myeloid leukemia (T-AML) or AML with myelodysplasia-related changes (AML-MRC) in children and adults. It was first introduced by Celator Pharmaceuticals Inc in its drug Vyxeos on Aug 3, 2017.


Cytarabine; Daunorubicin Patents

Given below is the list of patents protecting Cytarabine; Daunorubicin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyxeos US10028912 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US10166184 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US10835492 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US7850990 Compositions for delivery of drug combinations Jan 23, 2027 Celator Pharms
Vyxeos US8022279 Liposomal formulations of anthracycline agents and cytidine analogs Sep 14, 2027 Celator Pharms
Vyxeos US8092828 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Apr 01, 2029 Celator Pharms
Vyxeos US8431806 Liposomal formulations of anthracycline agents and cytidine analogs Apr 22, 2025 Celator Pharms
Vyxeos US8518437 Lipid carrier compositions with enhanced blood stability Jun 07, 2026 Celator Pharms
Vyxeos US9271931 Compositions for delivery of drug combinations Jan 23, 2027 Celator Pharms


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳